Gilead Prices $2 Billion of Senior Unsecured Notes
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall St mixed as Middle East tensions eclipse tech strength
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Gilead Sciences (GILD) shares oversold argues BofA
September 8, 2023 8:54 AM EDTBofA analyst Geoff Meacham upgraded shares of Gilead Sciences (NASDAQ: GILD) to Buy from Neutral, with a price target of $95, up from $88 per share, in a note to clients on Friday.
The analyst told investors that the pharmaceutical company's HIV drug upside remains... More
